Skip to content

AORTA - ABATON for RheumaToid Arthritis

AORTA - ABATON for RheumaToid Arthritis - AORTA

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00024205
Enrollment
225
Registered
2021-03-03
Start date
2021-05-18
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M05 M06

Interventions

Group 1: The intervention group receives ABATON RA with initial shared decision making (SDM) at the beginning of treatment and for the recording of treatment-relevant patient-reported outcomes (PRO) b

Sponsors

ABATON GmbH
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Legally valid consent of the patient has been given - Age = 18 years - Medical diagnosis of RA according to EULAR / ACR criteria. - Access to an internet-enabled device, e.g. smartphones, tablet PC or laptop or computer with a modern browser - Possession of a mobile phone number - The ability to speak and understand German

Exclusion criteria

Exclusion criteria: - Patients whose informed consent has not been obtained - Patients participating in other interventional studies - Persons who are in a dependent / employment relationship with the sponsor or investigator. - Persons in institutionalisation due to a court or administrative order. - Patients with any of the following concomitant therapies that have taken place or are ongoing: ABATON as a digital health application

Design outcomes

Primary

MeasureTime frame
The primary objective of the study is to demonstrate that the care of patients with rheumatoid arthritis is improved by the structured digital recording of PROs via ABATON, by facilitating, digitally-assisted patient-centered care based on the T2T principle improves the experienced health status based on the RAID.

Secondary

MeasureTime frame
- Reduction of experienced disease activity - Improvement of quality of life - Reduction of rheumatism-associated symptoms (pain, morning stiffness) - Reduction of disease activity according to DAS28, CDAI, SDAI - Increase in patient conversion rate from non-remission to remission - Increase of physical functions in daily life - Improvement of doctor-patient relationship - Increase in adherence to drug therapy - Increase in patient sovereignty - Increase in subjective work ability - Increase in adherence to guidelines through increased adherence to the T2T principle - Increase in cost-effectiveness

Countries

Germany

Contacts

Public ContactJohannes Knitza

Medizinische Klinik 3 Uniklinikum Erlangen

johannes.knitza@uk-erlangen.de091318535000

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026